AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03673215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin
Description: Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
Study NCT03673215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
Study NCT03673215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin
Description: Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
Study NCT03673215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
Study NCT03673215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin
Description: Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
Study NCT02628743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olesoxime
Description: Participants will receive homogeneous suspension of olesoxime.
Study NCT01796613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Ring - intermittent regimen
Description: NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
Study NCT01796613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Ring - continuous regimen
Description: NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
Study NCT01871415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: pre-existing background regimen and dose
Study NCT01871415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: matching aleglitazar placebo orally daily
Study NCT04463238 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Guided cartilage regeneration membrane
Description: On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.
Study NCT04578639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
Study NCT04578639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
Study NCT03692130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness, Acceptance and Commitment-Therapy
Description: Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.
Study NCT03692130 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Jacobson
Description: Relaxation treatment in technique of Jacobson
Study NCT01957722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Surgical procedure which creates a marrow clot in the prepare cartilage defect.
Study NCT01957722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NOVOCART 3D
Description: combination product- biologic (autologous chondrocytes) /device (scaffold) implant
Study NCT00941785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-PQ
Description: Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days
Study NCT00941785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-AQ
Description: Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg
Study NCT01915082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31).
Study NCT01915082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ora-Plus
Description: Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31).
Study NCT02716428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Study NCT02716428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-6450
Study NCT04463238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Operate in accordance with the clinical microfracture surgery method.
Study NCT04463238 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microfracture
Description: Operate in accordance with the clinical microfracture surgery method.
Study NCT03690674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Enhancement for ADHD Program
Description: The LEAP intervention consists of 3 components: 1) an enhanced 8-week, group-based BMT curriculum, 2) parent and child use of the Garmin daily activity tracker accompanied by personalized goal setting, and 3) parent participation in a private Facebook group to encourage PA goal achievement and promote social support and positive parenting.
Study NCT01300949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spaeth/Richman Contrast Sensitivity Test
Description: internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes that decrease in contrast by fading to a white background.
Study NCT02716428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT01623583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Needle Phobia Intervention
Description: The enhanced intervention will include the standard intervention, with two enhancements:~* The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch~* Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity.
Study NCT01300949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pelli-Robson Contrast Sensitivity Chart
Description: wall chart contrast sensitivity test measuring central vision using black letters that decrease in contrast by fading to a white background.
Study NCT01623583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Needle Phobia Intervention
Description: The standard intervention will include the following components:~1. Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.~2. Basic training on relaxation breathing~3. Brief video of a patient overcoming needle phobia~4. Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle
Study NCT03036696 — intervention group
Intervention type: OTHER
Intervention: Pregnant Mothers Interview
Description: Pregnant mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection and preferences for methods related to non-invasive sample collection.~Data collection for pregnant mothers includes Clinical Health Update (3rd trimester) and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab.
Study NCT03036696 — intervention group
Intervention type: OTHER
Intervention: Breastfeeding Mothers Interview
Description: Breastfeeding mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection, and preferences for methods related to non-invasive sample collection.~Data collection for breastfeeding mothers includes Clinical Health update (post-natal), Infant Feeding, and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab.
Study NCT01324908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extracorporeal photopheresis
Description: Undergo ECP
Study NCT01324908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04026997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-102 Dose 1
Description: CIN-102 Dose 1
Study NCT04026997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-102 Dose 2
Description: CIN-102 Dose 2
Study NCT04026997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-102 Dose 3
Description: CIN-102 Dose 3
Study NCT04026997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04026997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01862874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501
Description: Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant
Study NCT01862874 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulated with AAHS adjuvant
Study NCT01475994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grass pollen : Dactylis glomerata
Description: The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
Study NCT01475994 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Challenge with clean air
Description: The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
Study NCT03072147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: 20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
Study NCT03072147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
Study NCT01898962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete Surgical Removal
Study NCT01898962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Study NCT01595997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLX105
Description: intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
Study NCT01595997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DLX105
Description: intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
Study NCT01898962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ablative external beam radiation dose
Study NCT01898962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal surgical removal plus ablative radiation dose
Description: Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
Study NCT01898962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioembolization
Description: radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
Study NCT04260672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Centred Health Dialog (CCHD)
Description: The universal part of CCHD means a structured dialogue between the nurse and the child in presence of its parents using eight illustrations based on the most important practices associated with overweight in preschool children: fruit and vegetables consumption, intake of sweetened beverages and portion size, physical activity, sedentary behaviour tooth brushing and sleep routines. The health dialog is completed by demonstrating the BMI-growth chart to show BMI development to give parents an accurate weight perception, identify overweight and support parental readiness towards a healthy lifestyle.~When the child is identified with an overweight or obesity, the entire family is invited to participate in the targeted part of CCHD: the Family Guidance, a family consultation based on the evidence based Standardized Obesity Family Therapy (Nowicka, 2011).
Study NCT03150199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology + Motivational Interviewing
Description: Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 8 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered step-wise within sessions (rather than intertwined).
Study NCT03150199 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MI-based Health Education Intervention
Description: Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments. Motivational interviewing topics (e.g., pros and cons of behavior change, importance and confidence of behavior change, identification of barriers and resources to change) will be presented related to each health behavior.
Study NCT01351922 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionaire by interview.
Study NCT03472183 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: biopsies of colon
Description: Removal of additional biopsies of colon during the course of a colonoscopy planned for usual medical follow-up of patient
Study NCT01770756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Training
Study NCT03743376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421(25 mg/kg) Q2W
Description: Monoclonal antibody by IV infusion plus standard ART
Study NCT03743376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421(25 mg/kg) Q4W
Description: Monoclonal antibody by IV infusion plus standard ART
Study NCT00517413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120, 200 or 360 micrograms sc or iv monthly, starting dose
Study NCT04076618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vest
Description: Weighted Vest worn > or = 8 hours per day
Study NCT01881360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: A diet that is free of the gluten component
Study NCT01881360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: A standard hypocaloric diet with a daily 1500 caloric intake.
Study NCT02643680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel biocellulose wound dressing
Description: The novel biocellulose dressing will used as a primary dressing at one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
Study NCT02643680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bactigras
Description: Bactigras will used as a primary dressing at another one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
Study NCT04076618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise Training
Description: Structured exercise training 3 days a week
Study NCT04076618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight loss program
Description: a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
Study NCT04076618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss program
Description: a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
Study NCT04019392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Game Ready® device
Description: The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
Study NCT04019392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wetted Ice Bag with Elastic Wrap
Description: A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied using an elastic wrap to each participants' lower leg for 30 minutes. An elastic wrap applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half will be applied over the wetted ice bag.
Study NCT02615262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02615262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride
Study NCT02049788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low calorie/fat diet
Description: Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).